Showing 4711-4720 of 6036 results for "".
- DORC Launches Eva Nexushttps://modernod.com/news/dorc-launches-eva-nexus/2480687/DORC International announced the launch of Eva Nexus, a device designed to improve efficiency and control in retina, cataract and combined surgery. Eva Nexus introduces multiple innovations in surgical performance and efficiency, including SmartIOP that combines with the existing E
- Lighthouse Guild Opens Technology Center for People Who are Blind or Visually Impairedhttps://modernod.com/news/lighthouse-guild-opens-technology-center-for-people-who-are-blind-or-visually-impaired/2480685/Lighthouse Guild Technology Center, which offers people who are blind or visually impaired access to the latest assistive devices and state-of-the-art technology, celebrated its official opening. The Center occupies 11,000 square feet at Lighthouse Guild’s New York City headquarters and is
- Oculis Announces Licensing Agreement for Neuroprotective Drug Candidate for Glaucoma from Accure Therapeuticshttps://modernod.com/news/oculis-announces-licensing-agreement-for-neuroprotective-drug-candidate-for-glaucoma-from-accure-therapeutics/2480683/Oculis and Accure Therapeutics announced a licensing agreement granting Oculis exclusive global rights to develop and commercialize ACT-01, a potentially disease-modifying therapy to protect and prevent damage to the optic nerve and retina. Under the terms of the agreement, Accure
- Ocuphire Completes Enrollment in MIRA-4 Pediatric Safety Trial Evaluating Nyxol for Reversal of Mydriasishttps://modernod.com/news/ocuphire-completes-enrollment-in-mira-4-pediatric-safety-trial-evaluating-nyxol-for-reversal-of-mydriasis/2480680/Ocuphire Pharma announced that it has completed enrollment in the MIRA-4 trial evaluating the safety and efficacy of Nyxol eye drops to reverse pharmacologically-induced mydriasis (RM) in 23 pediatric subjects. Ocuphire worked closely with Oculos Develop
- Alcon Launches Clareon IOL Portfolio in the UShttps://modernod.com/news/alcon-launches-clareon-iol-portfolio-in-the-us/2480677/Alcon announced the launch of the Clareon family of IOLs in the United States. Utilizing an advanced IOL material, Clareon is designed to deliver consistent visual outcomes and clarity that lasts.[1-7] The Clareon clarity is born out of a glistening-free IOL material that has among
- LumiThera Completes Acquisition of Diopsyshttps://modernod.com/news/lumithera-completes-acquisition-of-diopsys/2480675/LumiThera announced the completion of its acquisition of Diopsys, a provider of modern visual electrophysiology medical devices. Diopsys is now a wholly owned subsidiary of LumiThera. Financial terms the transaction were not disclosed. EyewireTV's covereage of the acq
- Santen Establishes its First External Research Laboratory in Europe at the UCL Institute of Ophthalmology in Londonhttps://modernod.com/news/santen-establishes-its-first-external-research-laboratory-in-europe-at-the-ucl-institute-of-ophthalmology-in-london/2480674/Santen, in partnership with UCL Institute of Ophthalmology (IoO), has announced the company’s first external research laboratory in Europe. This development comes following ongoing and committed investment from Santen
- Accure Therapeutics Licenses Neuroprotective Drug Candidate to Oculishttps://modernod.com/news/accure-therapeutics-licenses-neuroprotective-drug-candidate-to-ophthalmology-company-oculus/2480672/Oculis and Accure Therapeutics announced a licensing agreement granting Oculis exclusive global rights to develop and commercialize ACT-01, a potentially disease-modifying therapy to protect and prevent damage to the optic
- Alpine and Shamir Extend Strategic Partnership Into Esports Worldhttps://modernod.com/news/alpine-and-shamir-extend-strategic-partnership-into-esports-world/2480654/Shamir has announced a multi-year extension to its partnership with Alpine F1 Team, becoming the optical performance partner of Alpine Esports Team. Shamir will provide ophthalmic assessments and improvement of gaming performance, and endurance through cutting edge lenses and
- Sight Sciences Launches “Don’t Wait for Too Late” Awareness Campaign for Glaucomahttps://modernod.com/news/sight-sciences-launches-dont-wait-for-too-late-awareness-campaign-for-glaucoma/2480649/Sight Sciences announced the launch of its “Don’t Wait for Too Late” educational campaign designed to raise awareness among the optometric community of minimally invasive glaucoma surgery (MIGS) as an earlier surgical intervention for glaucoma.